| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2010-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013505223-A |
| titleOfInvention |
Administration regimen for administering EpCAMxCD3 bispecific antibody |
| abstract |
A method (administration schedule) for administering an EpCAMxCD3 bispecific antibody to a human patient comprising: (a) sequentially administering a first dose of said antibody in a first period, followed by (b ) Continuously administering a second dose of the antibody in a second time period, wherein the second dose relates to a method that exceeds the first dose. The methods of the present invention (and also the dosage regimes of the present invention) are mediated to treat EpCAM positive epithelial cancer cells in human patients or by sequentially administering EpCAMxCD3 bispecific antibodies to human patients. It is also suitable for improving and / or preventing certain medical conditions. Furthermore, the invention relates to the use of an EpCAMxCD3 bispecific antibody for formulating a pharmaceutical composition for use in a method as defined in any one of the preceding claims. Also disclosed is a pharmaceutical package or kit comprising a first dose and a second dose as defined in the method / dosing regimen of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018533909-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7354079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021020906-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019135233-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016514098-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021178831-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020202829-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210086722-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7057801-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200123871-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459404-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102435747-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019515872-A |
| priorityDate |
2009-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |